EMERYVILLE, Calif., Feb. 24, 2020 — Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market close, and will host a corporate update conference call and webcast on Monday, March 2, 2020, at 4:30 PM Eastern Time.
|Conference Call Details|
|Monday, March 2nd @ 4:30pm Eastern Time / 1:30pm Pacific Time|
|Toll Free: 877-407-9716|
|Conference ID: 13699528|
About Zogenix Zogenix, Inc. is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
CONTACTS: Zogenix Melinda Baker Senior Director, Corporate Communications +1 (510) 788-8732 | [email protected]
Investors Brian Ritchie Managing Director, LifeSci Advisors LLC +1 (212) 915-2578 | [email protected]